RM

Ritu Lal Ph.d. (Management)

CEO And Co-founder at GEn1E Lifesciences

Ritu Lal, Ph.D., M.S. (Management) has an extensive work experience in the pharmaceutical and biotechnology industries. Ritu is currently the CEO and Co-Founder of GEn1E Lifesciences Inc. since 2018. Prior to this, they worked as a Consultant, providing advice to drug, device, and diagnostic companies on various aspects of development, strategy, and execution from 2013 to 2018.

From 2013 to 2015, Ritu served as a Project Team Leader at Mallinckrodt Inc., where they led cross-functional teams and completed clinical studies for two melanocortin drugs. Before that, they served as an Executive Director at XenoPort, Inc. from 2005 to 2012, leading the Clinical Pharmacology and Drug Metabolism and Pharmacokinetics functions.

Ritu also has experience at Roche Palo Alto as a Director and Clinical Lead in Clinical Pharmacology from 1999 to 2005, providing leadership and expertise for multiple cross-functional project teams. Ritu started their career at Abbott Laboratories in 1996 as a Research Pharmacokineticist, where they designed, analyzed, and reported clinical and preclinical studies.

Throughout their career, Ritu has demonstrated their expertise in clinical pharmacology, drug development, and regulatory affairs. Their work has contributed to the successful development and approval of multiple drugs in various therapeutic areas.

Ritu Lal, Ph.D., M.S., has an extensive education history in various fields. Ritu attended Stanford University from 2012 to 2013, where they completed the Sloan Program and obtained a Masters in Management with a focus on Business Administration and Management, General. Prior to that, from 1991 to 1996, Ritu Lal pursued their Doctor of Philosophy - PhD in Pharmaceutical Sciences at the University of Maryland School of Pharmacy. Ritu also holds a Master of Science (M.S.) degree in Pharmaceutical Sciences, which they earned from the University of Arizona from 1989 to 1991. Ritu Lal's educational journey began in 1985 when they obtained their Bachelor of Pharmacy (B.Pharm.) degree from the University Institute of Chemical Technology (formerly UDCT), specializing in Pharmacy, Pharmaceutical Sciences, and Administration.

Links

Previous companies

Mallinckrodt logo
Xenoport logo

Timeline

  • CEO And Co-founder

    May, 2018 - present